Brief: Adagene To Begin Phase 1 Study Of ADG138 For Advanced Solid Tumors In Q4 2026
22/09/2026 13:42
BRIEF-Adagene To Begin Phase 1 Study Of ADG138 For Advanced Solid Tumors In Q4 2026 Sept 22 (Reuters) - Adagene Inc. 978y.F:
ADAGENE ANNOUNCES NMPA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR ADG138, A NOVEL HER2XCD3 DOUBLE-MASKED BISPECIFIC T-CELL ENGAGER
ADAGENE - TO BEGIN PHASE 1 STUDY OF ADG138 FOR ADVANCED SOLID TUMORS IN Q4 2026
Source text: ID:nGNX7nhtw4
Further company coverage: [978y.F]
((Reuters.Briefs@thomsonreuters.com))
Recent news on Adagene
See all newsBrief: Adagene To Begin Phase 1 Study Of ADG138 For Advanced Solid Tumors In Q4 2026
Brief: Adagene Announces That Third Arc Bio Has Selected First Lead Candidate Under Amended Strategic Collaboration For Development Of Masked Cd3 T Cell Engagers Utilizing Safebody® Technology
Brief: Adagene Inc Announces Offering Of American Depositary Shares
Brief: Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)
Brief: Adagene Expands SAFEBody Deal With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate